Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Learning from Iressa – when and how to develop companion diagnostics

This article was originally published in Clinica

  • News
  • James Wade

Executive Summary

Datamonitor healthcare analyst James Wade looks back over the path to market taken by one of AstraZeneca's oncology drugs and outlines some key lessons for pharmaceutical companies developing personalised cancer therapies

You may also be interested in...



Biomarkers and Beyond: Learning from Iressa – when and how to develop companion diagnostics

James Wade looks back over the path to market taken by one of AstraZeneca's oncology drugs and outlines some key lessons for pharmaceutical companies developing personalised cancer therapies. This article is part of Scrip's Biomarkers and Beyond analysis. For more articles, data and multimedia features exploring the role of biomarkers in the future of the pharmaceutical industry, visit scripintelligence.com/biomarkers.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation

See All
UsernamePublicRestriction

Register

MT097611

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By